Hypertension, antihypertensive agents and outcomes following renal transplantation

Clinical Transplantation

Volumn 19, Issue 2, 2005, Pages 181-192

  Tutone, V K ^a   Mark, P B ^a   Stewart, G A ^a   Tan, C C ^a   Rodger, R S C ^a   Geddes, C C ^a   Jardine, Alan G ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Graft survival; Hypertension; Patient survival; Renal transplantation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT;

ADULT; AGE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DATA ANALYSIS; DEATH; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HYPERTENSION; KAPLAN MEIER METHOD; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL RECORD; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PULSE PRESSURE; RECIPIENT; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CAUSE OF DEATH; CREATININE; DIABETES COMPLICATIONS; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; HYPERTENSION; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RENAL REPLACEMENT THERAPY; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 15844420109     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2004.00315.x     Document Type: Article

References (33)

1. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000: 356: 147.
2. Luke RG. Hypertension in renal transplant recipients. Kidney Int 1987: 31: 1024.
3. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998: 53: 217.
4. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000: 11: 1735.
5. Jardine AG. Assessing cardiovascular risk profile of immunosuppressive agents. Transplantation 2001: 72: S81.
6. Holdaas H, Fellström B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomized, placebo controlled trial. Lancet 2003: 14: 2024.
7. Woo YM, Jardine AG, Clark AF et al. The influence of early graft function on patient survival following renal transplantation. Kidney Int 1999: 55: 692.
8. Wight JP, Brown CB, el Nahas AM. Effect of control of hypertension on progressive renal failure. Clin Nephrol 1993: 39: 305.
9. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996: 334: 13.
10. Peterson J, Adler S, Burkart J. Blood pressure control, proteinuria, and the progression of renal disease. Ann Inter Med 1995: 123: 754.
11. Breyer JA, Bain RP, Evans JK et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int 1996: 50: 1651.
12. Gjertson DW, Cecka JM. Determinants of long-term survival of pediatric kidney grafts reported to the United Network for Organ Sharing Kidney Transplant Registry. Pediatr Transplant 2001: 5: 5.
13. Ponticelli C. Progression of renal damage in chronic rejection. Kidney Int 2000: 57: S62.
14. Vazquez MA. Chronic rejection of renal transplants: new clinical insights. Am J Med Sci 2000: 320: 43.
15. Rao KV, Rose JK. Incidence, histological pattern, and clinical outcome of rejection episodes occurring in the late posttransplant period. Transplantation 1985: 40: 631.
16. Tejani A, Sullivan EK. The impact of acute rejection on chronic rejection: A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2000: 4: 107.
17. Massy ZA, Guijarro C, Wiederkehr MR, Ma JC, Kasiske BL. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 1996: 49: 518.
18. Hypolite IO, Bucci JR, Hshieh P et al. Acute coronary syndromes after renal transplantation in patients with end stage renal disease resulting from diabetes. Am J Transplant 2002: 2: 274.
19. Bleyer AJ. Relationship between underlying renal disease and renal transplantation outcome. Am J Kidney Dis 2001: 37: 1152.
20. Ojo AO, Hanson JA, Meier-Kriesche H et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001: 12: 589.
21. Kokado Y, Takahara S, Kameoka H, Okuyama A. Hypertension in renal transplant recipients and its effect on long-term renal allograft survival. Transplant Proc 1996: 28: 1600.
22. Harper SJ, Moorhouse J, Veitch PS et al. Nifedipine improves immediate, and 6- and 12-month graft function in cyclosporin A (CyA) treated renal allograft recipients. Transpl Int 1992: 5 (Suppl. 1): S69.
23. The Heart Outcome Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000: 342: 145.
24. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003: 361: 1843.
25. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987: 316: 1429.
26. Progress Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischemic attack. Lancet 2001: 358: 1033.
27. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failureMetoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999: 353: 2001.
28. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II)a randomised trial. Lancet 1999: 353: 9.
29. The CAPRICORN Investigators. Effects of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001: 357: 1385.
30. ALERT Study Investigators. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analysis of the ALERT Study. Am J Transplant 2004: 4: 1.
31. Port FK, Hulbert-Shearon TE, Wolfe RA et al. Predialysis blood pressure and mortality risk in a national sample of maintenance haemodialysis patients. Am J Kidney Dis 1999: 33: 507.
32. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier P, Adda H. Arterial media calcification in end stage renal disease: impact on all-cause and cardiovasular mortality. Nephrol Dial Transplant 2003: 18: 1731.
33. London GM, Guerin A. Influence of arterial pulse and reflective waves on systolic blood pressure and cardiac function. J Hypertens 1999: 17: S3.